Like Countable?

Install the App

house Bill H.R. 2315

Preserving Access to Orphan Drugs Act of 2013

bill Progress

  • Not enacted
    The President has not signed this bill
  • The senate has not voted
  • The house has not voted
      house Committees
      Committee on Energy and Commerce
      Committee on Ways and Means
    IntroducedJune 11th, 2013

Bill Details

Official information provided by the Congressional Research Service. Learn more or make a suggestion.
The Congressional Research Service writes summaries for most legislation. These summaries are listed here. Countable will update some legislation with a revised summary, title or other key elements.

Suggest an update to this bill using our form.


Preserving Access to Orphan Drugs Act of 2013

Official Title

To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers.


Preserving Access to Orphan Drugs Act of 2013 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions (orphan drug) from the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. Makes this Act effective as if included in PPACA.

    There are currently no opinions on this bill, be the first to add one!